Levadopa Related Compound A
| Code | Size | Price |
|---|
| TAR-T20396-50mg | 50mg | £1,099.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Levadopa Related Compound A is the 6-hydroxy derivative of the amino acid L-DOPA with neurotoxic properties. Exogenously administered 6-Hydroxy-L-DOPA is biotransformed by an amino acid decarboxylase to the highly potent and catecholamine-selective neurotoxin, 6-Hydroxydopamine.
CAS:
27244-64-0
Formula:
C9H11NO5
Molecular Weight:
213.189
Purity:
0.98
SMILES:
N[C@@H](Cc1cc(O)c(O)cc1O)C(O)=O
References
1. Luurtsema G, Boersma HH, Schepers M, de Vries AMT, Maas B, Zijlma R, de Vries EFJ, Elsinga PH. Improved GMP-compliant multi-dose production and quality control of 6-[(18)F]fluoro-L-DOPA. EJNMMI Radiopharm Chem. 2017;1(1):7. doi: 10.1186/s41181-016-0009-1. Epub 2016 Apr 4. PubMed PMID: 29564384; PubMed Central PMCID: PMC5843807.
2. Pinna A, Pontis S, Borsini F, Morelli M. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse. 2007 Aug;61(8):606-14. PubMed PMID: 17476684.
3. Yamato H, Kannari K, Shen H, Suda T, Matsunaga M. Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport. 2001 May 8;12(6):1123-6. PubMed PMID: 11338177.
4. Kostrzewa RM, Kostrzewa JP, Brus R. Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum. Amino Acids. 2000;19(1):183-99. PubMed PMID: 11026489.